Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

Annals of Clinical and Translational Neurology

Volumn 3, Issue 3, 2016, Pages 216-225

  Rojas, Julio C ^a   Karydas, Anna ^a   Bang, Jee ^a   Tsai, Richard M ^a   Blennow, Kaj ^b   Liman, Victor ^b   Kramer, Joel H ^a   Rosen, Howard ^a   Miller, Bruce L ^a   Zetterberg, Henrik ^b,c   Boxer, Adam L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFILAMENT PROTEIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY ASSESSMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUPERIOR CEREBELLAR PEDUNCLE; VALIDATION PROCESS;

EID: 84977620914     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.290     Document Type: Article

References (28)

1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359.
2. Kawashima M, Miyake M, Kusumi M, et al. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord 2004;19:1239-1240.
3. Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001;124:1438-1449.
4. Golbe LI. Progressive supranuclear palsy. Semin Neurol 2014;34:151-159.
5. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-1452.
6. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 1998;13:70-77.
7. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116-126.
8. Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014;13:676-685.
9. Gentil BJ, Tibshirani M, Durham HD. Neurofilament dynamics and involvement in neurological disorders. Cell Tissue Res 2015;360:609-620.
10. Neselius S, Brisby H, Marcusson J, et al. Neurological assessment and its relationship to CSF biomarkers in amateur boxers. PLoS One 2014;9:e99870.
11. Martinez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 2015;21:550-561.
12. Limberg M, Disanto G, Barro C, Kuhle J. Neurofilament light chain determination from peripheral blood samples. Methods Mol Biol 2016;1304:93-98.
13. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8:e75091.
14. Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247-2257.
15. Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595-599.
16. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
17. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552-1565.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-319.
20. O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol 2008;65:1091-1095.
21. Schwab R, England A. Projecton technique for evaluating surgery in Parkinson's disease. In: Gillinham F, Donaldson M, eds. Third symposium on Parkinson's disease research. Edinburgh, Scotland: ES Livingston, 1969. p. 152-157.
22. Villar LM, Picon C, Costa-Frossard L, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol 2015;22:1169-1175.
23. Surova Y, Nilsson M, Latt J, et al. Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Neuroradiology 2015;57:1079-91.
24. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015;84:1639-1643.
25. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014;29:1758-1766.
26. Pranzatelli MR, Tate ED, McGee NR, Verhulst SJ. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders. J Neuroimmunol 2014;266:75-81.
27. Meulendyke KA, Queen SE, Engle EL, et al. Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J Neurovirol 2014;20:591-602.
28. Tsai RM, Boxer AL. Clinical trials: past, current, and future for atypical Parkinsonian syndromes. Semin Neurol 2014;34:225-234.